January 25, 2011: Santhera Statement
Liestal, Switzerland, January 25, 2011 - Santhera Pharmaceuticals (SIX: SANN) announced today that - as part of its ordinary course of business - it is constantly evaluating its strategic options. As part of such process the company has had a high level dialogue with Newron Pharmaceuticals S.p.A. The continuation, content and outcome of such dialogue cannot be predicted. No further comments will be made.
* * *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. Santhera's first product, CatenaŽ, to treat Friedreich's Ataxia is marketed in Canada. For further information, please visit www.santhera.com.
CatenaŽ is a trademark of Santhera Pharmaceuticals.
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.